Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
Use mouse models to test existing and investigational drugs for Alzheimer's; focus on drug repositioning and combo therapy development.
Funder: National Institutes of Health
Due Dates: June 9, 2025 (New) | July 9, 2025 (Renewal/Resubmission/Revision) | October 6, 2025 (New) | November 6, 2025 (Renewal/Resubmission/Revision) | February 6, 2026 (New) | March 6, 2026 (Renewal/Resubmission/Revision) | and similar dates through March 2028
Funding Amounts: Up to $1,000,000 direct costs/year; max project period 5 years; NIA expects to fund 4–5 awards in FY26
Summary: Supports rigorous preclinical testing of repurposed and investigational drugs or drug combinations for Alzheimer’s disease and related dementias using mouse or cell-based models; clinical trials are not allowed.
Key Information: Applications must include both computational and experimental approaches; projects proposing only computational work or new drug development are not responsive.
Description
This NIH funding opportunity, led by the National Institute on Aging (NIA), seeks applications that combine computational and experimental approaches to rigorously test repurposed and investigational drugs, or drug combinations, for efficacy in Alzheimer’s disease (AD) and AD-related dementias (ADRD). The focus is on preclinical proof-of-concept studies using mouse or cell-based models (e.g., iPSCs, organoids), with the goal of enabling rational drug repositioning and the development of combination therapies for treatment and prevention of AD/ADRD.
Projects may also include testing drug candidates in combination with non-pharmacologic interventions (e.g., exercise, diet, cognitive training) to achieve robust translational outcomes. The initiative builds on NIA’s investment in data-driven drug repurposing and encourages multidisciplinary teams, including academic/industry partnerships, to prioritize and test promising candidates identified through bioinformatics and systems biology.
Clinical trials are not allowed under this opportunity.
